Edition:
United States

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

559.50GBp
7 Dec 2016
Change (% chg)

-1.00p (-0.18%)
Prev Close
560.50p
Open
560.00p
Day's High
566.50p
Day's Low
557.50p
Volume
705,627
Avg. Vol
580,916
52-wk High
739.50p
52-wk Low
554.97p

Latest Key Developments (Source: Significant Developments)

BTG says received approval from Health Canada for DC Bead Lumi
Thursday, 25 Aug 2016 07:00am EDT 

BTG PLC : Says received approval from Health Canada for DC Bead Lumi . Says anticipates securing regulatory clearances for additional radiopaque bead products in other markets worldwide .Says look forward to providing DC Bead Lumi to Canadian physicians during second half of 2016.  Full Article

BTG says pretax profit doubles for FY
Tuesday, 17 May 2016 02:01am EDT 

BTG Plc : FY pretax profit 57.5 million STG versus 26.7 million STG year ago .FY revenue rose 22 percent to 447.5 million STG.  Full Article

Galil medical announces agreement to acquisition by Btg Plc
Friday, 6 May 2016 08:38am EDT 

Btg Plc :Galil Medical announces agreement to acquisition by Btg Plc.  Full Article

BTG acquires Galil Medical
Friday, 6 May 2016 04:00am EDT 

BTG Plc : Acquisition . BTG Plc acquires Galil Medical, a leader in cryoablation . Will also pay up to $25.5 mln (£17.6m) in future regulatory and commercial milestone payments in respect of period to 31 December 2018 . BTG expects Galil Medical to be profitable and transaction to be earnings accretive in first full year of ownership. . Will acquire Galil Medical for an initial cash consideration of $84.5 mln (£58.3m) . Acquisition will be funded from BTG's existing cash resources .Evercore Partners International LLP advised BTG on transaction..  Full Article

BTG plc announces positive data from RENEW study of PneumRx Coil
Monday, 14 Dec 2015 02:00am EST 

BTG plc:Announces the outcome of the RENEW study, the pivotal US randomised controlled clinical trial comparing the safety and efficacy of the PneumRx endobronchial coil implant (EBCI) with a medical therapy control group in patients with homogeneous and/or heterogeneous severe emphysema.All primary and secondary endpoints of the study were met.  Full Article

BTG plc and Mirada Medical Ltd collaborate to develop dosimetry software solutions to optimise radioembolisation therapy in interventional oncology
Monday, 12 Oct 2015 02:00am EDT 

BTG plc and Mirada Medical Ltd:Announces important collaboration to develop dosimetry software solutions to optimise radioembolisation therapy with TheraSphere.Says companies are working together to provide a more personalised approach to radioembolisation for liver cancer patients, through easy-to-use and bespoke software that helps physicians plan the delivery of a specific radiation dose based on an individual patient's need.  Full Article

BTG Announces FDA Acceptance of Wellstat Therapeutics' NDA for Uridine Triacetate as Antidote to Overexposure to Chemotherapy Drug 5-Fluorouracil
Thursday, 10 Sep 2015 08:00am EDT 

BTG plc:Announces that Wellstat Therapeutics' new drug application (NDA) for uridine triacetate has been accepted for review by the United States Food and Drug Administration.Says the NDA seeks FDA approval of uridine triacetate as treatment for patients at risk of serious toxicity following an overdose of the chemotherapy agent 5-fluorouracil (5-FU) and patients exhibiting symptoms of serious toxicity within 96 hours of 5-FU administration.  Full Article

BTG Plc's Varithena received approval from Health Canada
Thursday, 6 Aug 2015 07:00am EDT 

BTG Plc:Health Canada has issued notice of compliance approving Varithena (polidocanol injectable foam), prescription medicine used to treat varicose veins.Varithena is indicated for treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of great saphenous vein (GSV) system above and below knee.  Full Article

BTG plc announces REVOLENS Study Results
Tuesday, 19 May 2015 02:02am EDT 

BTG plc:Presents top line data showing that REVOLENS, a randomized, controlled trial sponsored by the French Ministry of Health, met its primary endpoint.Says results show the PneumRx endobronchial coil is superior to the standard of care for improving exercise capacity in patients with severe emphysema at 6 months as measured by the 6 minute walk test.  Full Article

BTG Plc raises FY 2015 revenue guidance
Thursday, 5 Feb 2015 10:04am EST 

BTG Plc:Says that FY 2015 revenue to be in range 345 - 360 million pounds; previous guidance was 330 - 345 million pounds.New guidance reflects acquisition of PneumRx Inc, which completed on Jan. 7, and reversal of adverse foreign exchange impact reported for six months to Sept. 30, 2014.FY 2015 revenue of 353 million pounds - Thomson Reuters I/B/E/S.  Full Article

BRIEF-BTG reports 24 pct rise in first half revenue to 285.4 mln stg

* Says business has performed well during first half, and outlook for full year is strong